announced Tuesday that it resumed shipment of fluticasone propionate nasal spray, a substitute for
Par had stopped all shipments since Feb. 23 after a temporary restraining order was granted to GSK by the U.S. District Court for the District of Maryland.
On Monday evening, the court denied GlaxoSmithKline's motion to set aside the Food and Drug Administration's approval of the generic spray, and the restraining order was allowed to expire.
Annual sales of Flonase in the U.S. exceed $900 million.
Shares of Par Pharmaceutical rose 32 cents, or 1.1%, to $28.99 Tuesday.
This story was created through a joint venture between TheStreet.com and IRIS.